PTC Therapeutics, Inc.
$56.42-$1.91 (-3.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $5.9B
- P/E
- 8.6x
- EV / EBITDA
- 7.5x
- Revenue
- $1.7B
- Net margin
- 39.4%
- ROCE
- 35.5%
Price chart
Technical chartScreen technicals →-26.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -10.3%
- 3M
- -20.0%
- 6M
- -20.6%
- 1Y
- -26.2%
- 5Y
- +41.0%
52-week range
Day change -$1.91 (-3.3%) from $58 to $56 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PTCT, bought on each weekday since 2021.
News & filings
What PTC Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Operating margin of 49.5% against a peer median of 15.0%.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Read moreShow less
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 81.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $5.9B
- P/E
- 8.6x
- EV / EBITDA
- 7.5x
- EV / Sales
- 3.8x
- P/S
- 3.4x
- 52-week high
- $89.55
- 52-week low
- $56.42
Profitability
- Operating margin
- 49.5%
- Net margin
- 39.4%
- EBITDA margin
- 51.3%
- ROE
- -332.5%
- ROCE
- 35.5%
- ROA
- 23.5%
- Asset turnover
- 0.60
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.7B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 114.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 35.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -287.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $411.2M
Solvency
- Current ratio
- 2.35
- Debt / Assets
- 0.93
- CFO / Net profit
- 1.04
- Cash / Market cap
- 33.2%
Where the revenue went
Of every $100 of FY2025 revenue, $39 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $47.0M |
| Revenue | Gross profit | $1.7B |
| Gross profit | Research and development | $455.3M |
| Gross profit | Selling, general and administrative | $347.1M |
| Gross profit | Other operating expenses | $24.8M |
| Gross profit | Operating income | $856.5M |
| Operating income | Pretax income | $696.6M |
| Operating income | Interest and other expense | $159.9M |
| Pretax income | Tax and other | $14.0M |
| Pretax income | Net income | $682.6M |
Revenue and net profit
Revenue grew 114.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $698.8M | -$559.0M |
| FY2023 | $937.8M | -$626.6M |
| FY2024 | $806.8M | -$363.3M |
| FY2025 | $1.7B | $682.6M |
Cash flows
FY2025: $711.2M from operations, $411.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$356.7M | -$509.1M |
| FY2023 | -$158.4M | -$279.0M |
| FY2024 | -$107.7M | -$181.9M |
| FY2025 | $711.2M | $411.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.7B+114.5%1Y
- EBITDA
- $887.7M
- Net profit
- $682.6M
- Cash from operations
- $711.2M
- Free cash flow
- $411.2M
- Revenue CAGR, 3Y
- 35.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.7B | $887.7M | $682.6M | $411.2M | -332.5% | +114.5% | -287.9% |
Monthly returns
Month-by-month returns of PTCT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.9B |
| Current assets | $2.3B |
| Non-current assets | $624.8M |
| Liabilities | $3.1B |
| Current liabilities | $968.4M |
| Non-current liabilities | $2.1B |
| Equity | -$205.3M |
| Paid-in capital | $2.7B |
| Retained earnings | -$3.0B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PTCT highlighted.
P/E against peers
PTCT trades at 8.6x earnings against a peer median of 17.5x (a 51% discount).
Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| PTC Therapeutics, Inc.PTCTthis companyP/E ↓ discount | $5.9B | 8.6x | — | -332.5% | 7.5x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Protagonist Therapeutics, Inc.PTGX | $6.6B | -50.8x | 10.8x | -21.2% | -41.4x |
| TG Therapeutics, Inc.TGTX | $6.2B | 13.9x | 9.6x | 69.0% | 47.5x |
| Teleflex IncorporatedTFX | $5.8B | -6.5x | 1.9x | -29.0% | 27.1x |
| Apellis Pharmaceuticals, Inc.APLS | $5.3B | 234.6x | 14.2x | 6.0% | 75.2x |
| Ligand Pharmaceuticals IncorporatedLGND | $4.7B | 38.0x | 4.6x | 12.2% | 25.3x |
| Indivior Pharmaceuticals, Inc.INDV | $4.4B | 21.1x | -44.7x | -212.1% | 15.1x |
| Peer median | — | 17.5x | 7.1x | -7.6% | 23.1x |
Year-to-date ROI
PTCT since 1 January, against earlier years.
Historical volatility
PTCT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -63.0% |
| FY2023 | -37.3% |
| FY2024 | -18.2% |
| FY2025 | 49.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.7B |
| Cost of revenueCost Of Revenue | $47.0M |
| Gross profitGross Profit | $1.7B |
| Operating expensesOperating Expense | $827.1M |
| Research and developmentResearch And Development | $455.3M |
| Selling, general and administrativeSelling General And Administration | $347.1M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $24.7M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $24.7M |
| Amortization | $24.7M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $24.7M |
| Total expensesTotal Expenses | $874.1M |
| Operating incomeOperating Income | $856.5M |
| Interest and other | |
| Pretax incomePretax Income | $696.6M |
| TaxTax Provision | $14.0M |
| Net incomeNet Income | $682.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.9B |
| Current assetsCurrent Assets | $2.3B |
| Non-current assetsTotal Non Current Assets | $624.8M |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.1B |
| Current liabilitiesCurrent Liabilities | $968.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.1B |
| EquityTotal Equity Gross Minority Interest | -$205.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $711.2M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $711.2M |
| Net income, continuing operationsNet Income From Continuing Operations | $682.6M |
| Depreciation and amortisationDepreciation And Amortization | $38.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $38.8M |
| Depreciation | — |
| Amortization cash flowAmortization Cash Flow | — |
| Amortization of intangiblesAmortization Of Intangibles | — |
| Amortization of securitiesAmortization Of Securities | -$18.0M |
| Stock-based compensationStock Based Compensation | $74.5M |
| Deferred taxDeferred Tax | $0.00 |
| Deferred income taxDeferred Income Tax | $0.00 |
| Operating gains and lossesOperating Gains Losses | $10.8M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $7.1M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $130.0k |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$9.7M |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | $3.4M |
| Asset impairmentAsset Impairment Charge | $1.0M |
| Change in working capitalChange In Working Capital | -$47.9M |
| Other non-cash itemsOther Non Cash Items | -$21.0M |
| Investing cash flowInvesting Cash Flow | -$862.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$862.0M |
| Capital expenditureCapital Expenditure | -$300.0M |
| Purchase of PP&EPurchase Of PPE | -$8.9M |
| Sale of PP&ESale Of PPE | $70.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$8.8M |
| Purchase of investmentsPurchase Of Investment | -$1.4B |
| Sale of investmentsSale Of Investment | $855.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$562.0M |
| Purchase of intangiblesPurchase Of Intangibles | -$291.1M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$291.1M |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $331.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $331.1M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$1.6M |
| Net debt issuedNet Issuance Payments Of Debt | -$1.6M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$1.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$1.6M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Stock options exercisedProceeds From Stock Option Exercised | $99.0M |
| Other financing chargesNet Other Financing Charges | $233.7M |
| Change in cashChanges In Cash | $180.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2,271.0% |
| Cash at the start of the yearBeginning Cash Position | $795.3M |
| Cash at the end of the yearEnd Cash Position | $998.3M |
| Free cash flowFree Cash Flow | $411.2M |
| Supplemental |
Learn while you research
Academy chapters picked for PTC Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 8.6 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Growth Investing115% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read